Recursion Pharmaceuticals' recent merger with Exscientia and positive trial updates have boosted investor interest. Despite a recent share price surge, the stock's one-year return remains negative. Market sentiment suggests potential undervaluation, but high price-to-sales ratio raises concerns about overvaluation.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing